Skip to main content

Table 3 Predictors of disease progression in the multivariate Cox regression analysis

From: Clinical significance of urinary inflammatory biomarkers in patients with IgA nephropathy

 

Multivariate analysis

Variables

HR (95% CI) b

P

BAFFa

1.94 (0.59–6.39)

0.28

VEGFR-2a

1.63 (0.70–3.77)

0.26

MCP-1a

1.88 (0.57–6.16)

0.30

RANTESa

0.99 (0.52–1.88)

0.97

CXCL10a

1.32 (0.44–3.96)

0.63

CXCL16a

1.61 (0.69–3.71)

0.27

EGFa

0.40 (0.17–0.95)

0.04

Endocana

1.60 (0.68–3.75)

0.28

Endostatina

1.37 (0.61–3.05)

0.45

GDF-15a

2.45 (1.01–5.94)

0.048

IFNγa

0.91 (0.53–1.58)

0.75

IL-6a

3.02 (1.05–8.64)

0.04

MBLa

1.92 (0.89–4.13)

0.10

Nephrina

1.03 (0.66–1.62)

0.89

TfRa

0.66 (0.17–2.55)

0.55

KIM-1a

1.85 (0.69–4.93)

0.22

  1. BAFF, B-cell-activating factor; CI, confidence interval; CXCL10, C–X–C motif chemokine 10; CXCL16, C–X–C motif ligand 16; DM, diabetes mellitus; HTN, hypertension; EGF, epidermal growth factor; eGFR, estimated glomerular filtration rate; GDF-15, growth/differentiation factor-15; HR, hazard ratio; IFNγ, interferon γ; IL-6, interleukin-6; KIM-1, kidney injury molecule-1; MBL, mannose-binding lectin; MCP-1, monocyte chemoattractant protein-1; PCR, protein–creatinine ratio; RANTES, regulated on activation, normal T cell expressed and secreted; TfR, transferrin receptor; VEGFR-2, vascular endothelial growth factor receptor-2
  2. aBiomarker values are expressed relative to urine creatinine concentration and then log-transformed
  3. bMultivariate analysis was conducted by adjusting for age, sex, HTN, eGFR, and PCR for each biomarker separately